DDInter576 DDInter1925
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Disulfiram {u} (Compound) upregulates {v} (Gene) SLC7A11
SLC7A11 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Disulfiram {u} (Compound) downregulates {v} (Gene) OXLD1
OXLD1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Disulfiram {u} (Compound) downregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Disulfiram {u} (Compound) upregulates {v} (Gene) DNAJB1
DNAJB1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Disulfiram {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Disulfiram {u} (Compound) upregulates {v} (Gene) SLC7A11
SLC7A11 {u} (Gene) regulates {v} (Gene) CRIP1
CRIP1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Disulfiram {u} (Compound) upregulates {v} (Gene) NFIL3
NFIL3 {u} (Gene) is regulated by {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Disulfiram {u} (Compound) upregulates {v} (Gene) CRIP1
CRIP1 {u} (Gene) is regulated by {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vemurafenib
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Disulfiram (Compound) upregulates SLC7A11 (Gene) and SLC7A11 (Gene) is upregulated by Vemurafenib (Compound)
Disulfiram (Compound) downregulates OXLD1 (Gene) and OXLD1 (Gene) is upregulated by Vemurafenib (Compound)
Disulfiram (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Vemurafenib (Compound)
Disulfiram (Compound) upregulates DNAJB1 (Gene) and DNAJB1 (Gene) is downregulated by Vemurafenib (Compound)
Disulfiram (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Vemurafenib (Compound)
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Disulfiram (Compound) upregulates SLC7A11 (Gene) and SLC7A11 (Gene) regulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Vemurafenib (Compound)
Disulfiram (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is regulated by IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Vemurafenib (Compound)
Disulfiram (Compound) upregulates CRIP1 (Gene) and CRIP1 (Gene) is regulated by ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound)